News Headlines

  1. George Medicines Signs Exclusive Licensing Agreement With Ahngook Pharmaceutical To Commercialize GMRx2 In Korea 3/11/2026

    George Medicines, a late-stage biopharmaceutical company focused on addressing significant unmet needs in cardiometabolic disease, has entered into an exclusive licensing and supply agreement with Ahngook Pharmaceutical Co. Ltd (“Ahngook Pharm”) (KOSDAQ: 001540), of Seoul, Korea, granting Ahngook Pharm exclusive rights to seek regulatory approval of, and to commercialize, GMRx2 in Korea.

  2. Bavarian Nordic And Serum Institute Of India Expand Strategic Partnership With Chikungunya Vaccine Manufacturing Agreement 3/11/2026

    Copenhagen, Denmark Bavarian Nordic A/S (OMX: BAVA) today announced an expansion of the strategic partnership with Serum Institute of India Pvt. Ltd. (SII) to include a contract manufacturing agreement covering a full tech transfer of the manufacturing process for the chikungunya vaccine (CHIKV VLP) from Bavarian Nordic to SII to allow for scaling of capacity to enable future supply to endemic low- and middle-income countries (LMICs).

  3. Catalent And GelMEDIX Enter Global Partnership For The Development And Clinical Manufacturing Of iPSC-Derived Cell Therapies In Ocular And Retinal Diseases 3/11/2026

    GelMEDIX Inc., a biotechnology company developing regenerative therapies to restore vision, and Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced a global partnership to access Catalent’s GMP-induced pluripotent stem cells (iPSC) and Catalent’s cell therapy manufacturing expertise and capabilities to support the development and clinical manufacturing of GelMEDIX’s iPSC-derived cell therapies to treat ocular and retinal diseases.

  4. Samsung Biologics Announces Collaboration With Lilly To Establish New Gateway Labs Site In Korea 3/10/2026

    Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), announced a collaboration agreement with Eli Lilly and Company (Lilly) to establish a Lilly Gateway Labs (LGL) site in Korea.

  5. mAbxience Selects Genedata Bioprocess To Automate End-To-End CDMO Workflows 3/10/2026

    Genedata, a Danaher company and the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that mAbxience has selected the Genedata Bioprocess® enterprise platform to structure and harmonize all bioprocess development data across its operations.

  6. Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration To Support BOT+BAL Manufacturing Needs 3/10/2026

    Agenus Inc., a leader in immuno-oncology innovation, today announced that it has triggered the first $20M contingent payment under its previously disclosed strategic collaboration with Zydus Lifesciences Ltd.

  7. Polyrizon Announces GMP Manufacturing Of Clinical Trial Material (CTM) With Eurofins CDMO AmatsiAquitaine S.A.S For Planned U.S. Clinical Study 3/10/2026

    Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced the successful production of a Good Manufacturing Practice (GMP) batch of clinical trial material (CTM) for its lead product candidate.

  8. Ministerial Visit To Athlone Laboratories: A Vision For The Future Of Critical Medicines In Ireland 3/9/2026

    Athlone Laboratories attracted three of the government’s biggest champions for the Irish pharma sector: Peter Burke, Minister for Enterprise, Tourism and Employment; Rory Mullen, Head of BioPharma and Food at IDA Ireland; and Noeleen Hussey, Regional Manager – West Region, IDA Ireland.

  9. Rapport Therapeutics And Tenacia Biotechnology Announce Strategic Collaboration For The Development And Commercialization Of RAP-219 In Greater China 3/9/2026

    Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport”) a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological and psychiatric disorders, and Tenacia Biotechnology (Hong Kong) Co., Ltd (“Tenacia”), a commercial-stage biopharmaceutical company dedicated to developing innovative therapeutics for patients with underserved neurological disorders, today announced a collaboration granting Tenacia exclusive rights to develop and commercialize RAP-219 in Greater China, including in mainland China, Hong Kong, Macau and Taiwan.

  10. Lonza And Genetix Biotherapeutics Extend Commercial Manufacturing Agreement For ZYNTEGLO 3/9/2026

    Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), and Genetix Biotherapeutics Inc. (Genetix), a commercial-stage biotechnology company dedicated to delivering genetic therapies for patients with severe rare diseases, today announced the extension of their long-term commercial manufacturing agreement. Under the expanded agreement, Lonza will expand manufacturing capacity to support growing demand for Genetix’s ZYNTEGLO, the only FDA-approved gene therapy for pediatric and adult patients with transfusion-dependent beta-thalassemia.